We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
AVTX | Avalo Therapeutics Inc | 17.44 | 12.69 | 267.16% | 404,254 |
BCG | Binah Capital Group Inc | 20.16 | 10.66 | 112.21% | 124,081 |
PIK | Kidpik Corporation | 5.50 | 2.23 | 68.20% | 1,101,894 |
SSKN | Strata Skin Sciences Inc | 0.66 | 0.2151 | 48.35% | 2 |
KTRA | Kintara Therapeutics Inc | 0.12 | 0.0305 | 34.08% | 9,140,675 |
PEGR | Project Energy Reimagined Acquisition Corporation | 11.58 | 2.92 | 33.72% | 314 |
AKBA | Akebia Therapeutics Inc | 2.685 | 0.445 | 19.87% | 2,288,998 |
MYMD | MyMD Pharmaceuticals Inc | 2.79 | 0.44 | 18.72% | 3 |
SVMH | SRIVARU Holding Ltd | 0.3137 | 0.0487 | 18.38% | 32,217 |
BRKH | BurTech Acquisition Corporation | 13.00 | 2.00 | 18.18% | 439 |
KYCH | Keyarch Acquisition Corporation | 8.00 | 0.9946 | 14.20% | 153 |
Kidpik Corp. (NASDAQ: PIK) ("kidpik” or the "Company"), an online clothing subscription-based e-commerce company, today announced that the Company received written notification from the Listing Qualification Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that is has regained full compliance with the Minimum Bid Price Requirement.
SAN DIEGO, March 27, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the expansion of the inclusion criteria in the open label 15- patient REM-001 study in cutaneous metastatic breast cancer (CMBC) to include patients receiving pembrolizumab (KEYTRUDA®) for at least three months at screening.
PLYMOUTH MEETING, Pa., March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will participate in The Novel Therapeutics Forum hosted by Citizens JMP at Penn Medicine at 10:00 am ET on April 2, 2024.
Once-Daily Oral HIF-PH Inhibitor Activates Physiologic Response to Manage Anemia Akebia's Launch Strategy Developed to Drive Toward a Potential New Oral Standard of Care Company to Host Conference Call on Thursday, March 28 at 8:00 AM ET CAMBRIDGE, Mass., March 27, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo® (vadadustat) Tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at ...
Rank | Ticker | Board Name | Posts (24h) |
---|---|---|---|
LWLG | Lightwave Logic Inc | 196 | |
FBEC | FBEC Worldwide Inc | 62 | |
IQST | iQSTEL Inc | 45 | |
4 | SPZI | SPOOZ Inc | 66 |
5 | KBLB | Kraig Biocraft Laboratories Inc | 43 |
6 | NB | Niocorp Developments Ltd | 18 |
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 70,436.26 | 971.69 | 1.40% | 1.38T | 7,376,737,190 |
ETH | Ethereum | 3,577.81 | 77.75 | 2.22% | 430.37B | 3,937,733,128 |
USDT | Tether USD | 0.9995 | 0.00006 | 0.01% | 97.79B | 1,037,898,827 |
BNB | Binance Coin | 586.49 | 12.36 | 2.15% | 92.92B | 517,323,115 |
SOL | Solana | 186.38 | 0.260 | 0.14% | 82.22B | 1,821,036,200 |
STETH | stETH | 3,575.69 | 111.26 | 3.21% | 35.06B | 13,509,541 |
XRP | Ripple | 0.6214 | 0.0099 | 1.62% | 33.94B | 598,304,485 |
DOGE | Dogecoin | 0.20391 | 0.01387 | 7.30% | 29.24B | 2,190,603,403 |
USDC | USD Coin | 0.99997 | -0.00003 | 0.00% | 28.07B | 1,500,108,899 |
ADA | Cardano | 0.6484 | 0.0008 | 0.12% | 22.83B | 201,979,539 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions